Chronic kidney disease: A coronary heart disease equivalent?

The Lancet

Volumn 380, Issue 9844, 2012, Pages 783-785

  Polonsky, Tamar S ^a   Bakris, George L ^b  

^a UChicago Medicine   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY RISK; DIABETES MELLITUS; DIALYSIS; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NOTE; PRIORITY JOURNAL; PROTEINURIA; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84865593071     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60772-7     Document Type: Note

References (11)

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-97.
2. NHS, National Institute for Health and Clinical Excellence. NICE clinical guideline 67. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (May 2008, reissued March 2010). http://www.nice. org.uk/nicemedia/pdf/CG67NICEguideline.pdf (accessed May 2, 2012).
3. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97. (Pubitemid 47016250)
4. Tonelli M, Muntner P, Lloyd A, et al, for the Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; published online June 19. DOI:10.1016/S0140-6736(12)60572-8.
5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
6. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137: 563-70.
7. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121: 357-65.
8. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-92.
9. Hyre AD, Fox CS, Astor BC, et al. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007; 49: 37-45. (Pubitemid 44932194)
10. United States Renal Data System Annual Data Report. Identification and care of patients with chronic kidney disease. http://www.usrds. org/2011/view/v1-02.asp?zoom-highlight=lipids (accessed May 5, 2012).
11. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91. (Pubitemid 351214285)